Nexium (Esomeprazole)

Esomeprazole works by irreversibly inhibiting the H+/K+ ATPase enzyme, also known as the proton pump, on the secretory surface of gastric parietal cells. This inhibition blocks the final step of acid production, leading to a sustained reduction in gastric acidity and an increase in gastric pH.

The specific dose and duration of Nexium therapy are determined by the prescribing clinician based on the patient’s condition, severity, and response to treatment. Healthcare professionals tailor the regimen to achieve optimal acid control while minimizing potential risks.

The safety of Nexium in pregnancy and lactation has not been definitively established. Clinicians should evaluate the potential benefits against possible risks and consider alternative therapies when appropriate. Women who are pregnant, planning pregnancy, or breastfeeding should discuss treatment options with their healthcare provider.

To place an order, submit an enquiry on the Nexium product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will request verification of trade or institutional credentials. After confirmation, the team provides pricing, availability, shipping details (including any cold‑chain requirements), and assists with import documentation.

Nexium (esomeprazole) belongs to the proton pump inhibitor (PPI) class, which provides more potent and longer‑lasting acid suppression than H2‑receptor antagonists such as ranitidine. Compared with other PPIs, esomeprazole offers a slightly higher bioavailability and consistent acid control, making it a preferred option for severe or refractory acid‑related disorders.

Nexium intravenous solution should be stored at 2‑8 °C (refrigerated). Keep the product in its original packaging, protect it from light, and avoid freezing or shaking the container to maintain stability and potency.

Nexium is supplied as an intravenous solution and is administered by slow infusion into a vein under the supervision of qualified healthcare personnel. The infusion rate and duration are determined by the prescribing clinician according to the patient’s clinical needs.

Serious risks include severe allergic reactions such as anaphylaxis, Clostridioides difficile‑associated colitis, significant hypomagnesemia, and hepatic enzyme elevations. Patients should be monitored for signs of these conditions, and therapy should be discontinued if any serious adverse event occurs.

Nexium is contraindicated in patients with known hypersensitivity to esomeprazole or any component of the formulation. Caution is also advised for individuals with severe liver disease, those taking medications that may interact critically, and patients for whom alternative acid‑reducing therapies are more appropriate.